Repligen Corporation Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$242.6M
Industry:Biotech
Founded:1981
Lead Investor(s):J.P. Morgan Securities LLC, Stephens Inc
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Repligen Corporation's estimated annual revenue is currently $50.2M per year.
  • Repligen Corporation received $138.0M in venture funding in June 2017.
  • Repligen Corporation's estimated revenue per employee is $155,000
  • Repligen Corporation's total funding is $242.6M.

Employee Data

  • Repligen Corporation has 324 Employees.
  • Repligen Corporation grew their employee count by 22% last year.
  • Repligen Corporation currently has 4 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
$7.1M4659%N/A
Tango Therapeut...
$9M5841%N/A
Compass Therape...
$15.8M10215%N/A
Cell Signaling ...
$75.6M488N/AN/A
Momenta Pharmac...
N/A212N/AN/A
Emulate
$14.7M95-17%N/A
ArQule
N/A90N/AN/A
Hamilton Storag...
$14.6M949%N/A
Alnylam Pharmac...
$74.9M122831%N/A
Transgenomic
N/A45N/AN/A
Missing a competitor? Contribute!?
Submit

Repligen is a bioprocessing-focused life sciences company bringing over 35 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies. Our manufacturing facilities are located at our Waltham, Massachusetts headquarters in the USA, and in Lund, Sweden, Weingarten, Germany , Rancho Dominguez, CA and Shrewsbury, MA. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.

keywords:Biotechnology,Healthcare,Pharmaceuticals

324

Number of Employees

$50.2M

Revenue (est)

4

Current Jobs

22%

Employee Growth %

$242.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Michael LaBreckSales Director, Tangenx Products
Jon SnodgresChief Financial Officer
Tony HuntChief Executive Officer
John McSweeneySenior Director Of Financial Planning And AnalysisEmail Available
Scott PearceManager of FP&A
Alan DionVice President FinanceEmail Available
Gautam ChoudharyVice President And General Manager-bioprocess SystemsEmail Available
Joe RealeDirector Of EngineeringEmail Available
Luis CostaQuality Manager
Linda FedericoDirector Customer ServiceEmail Available

Repligen Corporation News

09/08/2019 - What Should Investors Know About Repligen Corporation's ...

Based on Repligen Corporation's (NASDAQ:RGEN) earnings update in June 2019, analyst forecasts seem fairly subdued, as a 8.4% rise in ...

09/06/2019 - Digging Through Repligen Corporation (RGEN) Fundamentals

On Thursday, shares of Repligen Corporation (NASDAQ:RGEN) marked $94.23 per share versus a previous $90.85 closing price. With having ...

09/09/2019 - Here's Why Repligen Corporation (RGEN) Dropped -1.3%

In its most recent trading session, Repligen Corporation (RGEN) dropped by -1.3% – here is what that looked like (as of 2019-09-09): ...

Repligen Corporation Funding

DateAmountRoundLead InvestorsReference
2003-05-05$12.5MPrivate PlacementArticle
2014-06-20$4.0MUndisclosedArticle
2017-06-29$138.0MUndisclosedJ.P. Morgan Securities LLCArticle

Repligen Corporation Executive Hires

DateNameTitleReference
2011-08-12Robert A. SpurrVP Sales/Marketing/Chief Commercial OfArticle
2012-09-24Jonathan I LieberCFOArticle
2014-07-16Jon SnodgresChief Financial OfficerArticle
2016-10-19Ralf KuriyelSVP Research & DevelopmentArticle

Repligen Corporation Acquisitions

DateCompany NameAmountNotesReference
2010-03-05Article
2016-12-16TangenXArticle
2017-08-24Spectrum Communications & Consulting, Inc.Article